HYPOSENS H2020 Project

Cancer metastasis is responsible for 90% of cancer related deaths. In breast cancer, metastasis occurs mostly via the lymphatic system. The lymphatic nodes that are closest to a tumour are the most likely route for the cancer cells to first enter the lymphatic system and are referred to as the sentinel lymph nodes (SLN).
Diagnosing the presence of cancerous cells within the SLN is therefore critical to provide optimum treatment plans. The gold standard is currently the Sentinel Lymph Node Biopsy (SLNB). SLNB however comes with several drawbacks.
The HYPOSENS imaging system is strategically designed to offer a minimally invasive alternative to the SLNB. The device is a prognostic solution for clinicians towards, once validated more accurate and fast diagnosis and personalised treatment options.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 732794.

Company’s Keywords:

research, health, sentinel lymph node biopsy, cancer, medicine, breast cancer, oncology